Drug Trial Radar · NCT06694805
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
326
Actual
Start
Dec 2, 2024
Primary completion
Aug 19, 2026
Study completion Jun 9, 2028
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess how effective, safe, and long-lasting a long-acting antiretroviral therapy (ART) using CAB LA + RPV LA is for people with HIV who still have detectable virus levels despite being on oral ART. The study will also consider feedback from patients on their experience with this treatment.
Conditions
- HIV Infections
Interventions
CAB LA + RPV LADrug
Intramuscular injection administered monthly for first 2 initiation doses then every 2 months.
Oral ARTDrug
Oral medication provided to participants by the site/their regular healthcare professional (HCP) as part of their standard of care (SOC) treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with virologic suppression after the CAB LA + RPV LA treatment compared to oral ARTTime frame: At Month 6
Locations
85 sites in 8 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Aurora, Colorado
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
New Haven, Connecticut
GSK Investigational Site
Newark, Delaware
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Jacksonville, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Sarasota, Florida
GSK Investigational Site
West Palm Beach, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Decatur, Georgia
GSK Investigational Site
Macon, Georgia
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Baltimore, Maryland
GSK Investigational Site
Baltimore, Maryland
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Berkley, Michigan
GSK Investigational Site
Kansas City, Missouri
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Newark, New Jersey
GSK Investigational Site
Hawthorne, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
The Bronx, New York
GSK Investigational Site
The Bronx, New York
GSK Investigational Site
Greensboro, North Carolina
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Columbus, Ohio
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Seattle, Washington
GSK Investigational Site
Milwaukee, Wisconsin
GSK Investigational Site
Buenos Aires, Argentina
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.